摘要
目的探讨免疫组化(IHC)法检测乳腺癌HER-2蛋白表达和荧光原位杂交(FISH)法检测HER-2基因扩增的临床意义。方法分别采用IHC法及FISH法检测328例乳腺癌组织HER-2蛋白表达及基因扩增状态。结果 328例乳腺癌组织中,45例HER-2蛋白表达(3+)的病例中40例HER-2基因扩增,5例无扩增;118例HER-2蛋白表达(2+)的病例中有50例基因扩增,68例无扩增;165例HER-2蛋白表达(1+或0)的病例中有5例基因扩增;IHC和FISH两法检测结果阳性率的差异无统计学意义(P>0.05)。结论 IHC法检测乳腺癌HER-2蛋白表达可作为临床治疗的初筛,HER-2蛋白表达(2+)的病例应常规行荧光原位杂交法,以确定HER-2基因扩增状态。FISH法检测结果具有较高的稳定性和可靠性,联合IHC法可更准确和客观评价乳腺癌预后,并指导临床选用靶向药物治疗。
Objective To detect the expression of HER-2 protein by immunohistochemistry （IHC） and HER-2 gene am- plification by fluorescence in situ hybridization （FISH） in breast cancer and evaluate the clinical significance. Methods HER-2 gene amplification and HER-2 protein expression were examined by FISH and IHC respectively in 328 cases of breast cancer. Re- sults Of 45 patients with HER-2 protein expression （＋ ＋ ＋）, 40 cases showed positive HER-2 gene amplification. Of 118 pa- tients with HER-2 protein expression （＋ ＋）, 50 cases showed positive HER-2 gene amplification. Of 165 patients with HER- 2 protein expression （＋ or 0）, 5 cases showed positive HER-2 gene amplification. No significant difference was found in the results between these methods （P〈0.05）. Conclusion In the cases with positive and strongly positive expression of HER-2 protein, HER-2 gene amplification shall be detected. The immunohistochemical detection of breast cancer HER-2 protein ex- pression can be used as a initial clinical screening. In the cases of HER-2 protein expression （＋ ＋）, HER-2 gene amplification shall be detected. FISH has a higher stability and reliability than IHC. The combination with FISH and IHC used to detect the expression of HER-2 in breast cancer is the best way which guides the selection of targeted drug therapy and the evaluation of prognosis.
出处
《福建医药杂志》
CAS
2013年第4期55-57,共3页
Fujian Medical Journal
